Last 33,900 KRW
Change Today -500.00 / -1.45%
Volume 69.1K
096530 On Other Exchanges
As of 1:29 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

seegene inc (096530) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - 43,000
52 Week Low
12/22/14 - 29,350
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEEGENE INC (096530)

Related News

No related news articles were found.

seegene inc (096530) Related Businessweek News

No Related Businessweek News Found

seegene inc (096530) Details

Seegene, Inc. develops molecular diagnostics systems for various applications. It offers IVD reagets comprising respiratory pathogens for the detection of respiratory viruses and bacteria, pneumonia bacteria, and influenza A and influenza B virus; sexually transmitted infections causative pathogens detection product; human papillomavirus detection products; tuberculosis detection products; Magicplex sepsis real-time test screens; meningitis pathogens for the detection of viruses and bacteria causing human meningitis; and diarrhea pathogens for the detection of viruses and bacteria causing diarrhea. The company also provides Anyplex and Seeplex products for the detection of vanA, vanB, and vanC genes; two mutations causing clarithromycin-resistance; Apolipoprotein E genotypes from blood samples; hepatitis A, B and C virus; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, FNAB, H&E slides, and paraffin-embedded tissues; BCR/ABL fusion gene from blood and whole bone marrow; and CMV infection from whole blood and plasma. In addition, it offers automatic real time detection systems; liquid handling workstations and automated magnetic bead based nucleic acid extractions systems; PCR machines; LabChip, a nucleic acid separations system; and MultiNA, a microchip electrophoresis system. Seegene, Inc. has operations in Asia, Oceania, the Middle East, Africa, the United States, and South Korea, as well as central, northern, eastern, and west Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.

Founded in 2000

seegene inc (096530) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

seegene inc (096530) Key Developments

Seegene, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:00 AM

Seegene, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jong-Yoon Cheon, Founder, Chief Executive Officer and Chief Technology Officer.

Seegene Inc. Introduces Allplex(TM) Assays Based on MuDT(TM) Next-Generation qPCR Technology

Seegene Inc. announced that it is introducing the first three comprehensive Allplex(TM) assays using its next-generation qPCR technology, called MuDT(TM). The assay launch menu includes a 26-target Respiratory Full Panel, a 26-target Gastrointestinal Infection Full Panel, and a 27-target Sexually Transmitted Infection Full Panel. Seegene will feature its new Allplex(TM) infectious disease portfolio at the MEDICA 2014 trade fair in Düsseldorf, Germany, November 12-15, 2014, booth #E11/Hall 01. MuDT(TM), which was first introduced at the 2014 Clinical Lab Expo of the American Association for Clinical Chemistry (AACC) in July, is a disruptive qPCR technology that allows simultaneous detection and quantification of multiple target analytes in a single fluorescence channel, without melt curve analysis after amplification. With the introduction of these new Allplex(TM) assays, Seegene now provides the most comprehensive multiplexed PCR molecular infectious disease panels in the industry. Seegene is committed to the ongoing development of assays to expand the Allplex(TM) infectious disease portfolio and aims to submit for CE Mark on the first three assays in 2015.

Seegene, Inc. Unveils MuDT(TM) technology

Seegene Inc. announced 'MuDT(TM)' technology, the real-time PCR technology that will ignite a paradigm shift in the PCR instrument market. By doubling the multiplexing capacity of any existing real-time PCR instrument, MuDT(TM) will maximize the value of the installed base of real-time PCR instruments. MuDT(TM) technology will be unveiled at the 2014 Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), held in Chicago from July 29 to 31. MuDT(TM) technology can be applied to any existing real-time PCR instrument and transforms it into a more powerful system by doubling its multiplexing capacity without upgrading the hardware. Additional benefits of MuDT(TM) technology include: Easier detection of multiple targets in a single channel without requiring melt curve analysis after amplification. SNP genotyping (homozygous wild type or mutant, or heterozygous) in a single channel. Identification and quantification of multiple mutations at the same time in a single tube. Economical approach for high multiplexing and quantification by doubling channel availability. Freedom from well-to-well and instrument-to-instrument variations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
096530:KS 33,900.00 KRW -500.00

096530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 096530.
View Industry Companies

Industry Analysis


Industry Average

Valuation 096530 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEEGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at